GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Leap Therapeutics Inc (FRA:5MC) » Definitions » FFO

Leap Therapeutics (FRA:5MC) FFO


View and export this data going back to 2016. Start your Free Trial

What is Leap Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.


Leap Therapeutics Business Description

Traded in Other Exchanges
Address
47 Thorndike Street, Suite B1-1, Cambridge, MA, USA, 02141
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .